Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Slawomir Wojtowicz-Praga"'
Autor:
Avi I. Einzig, Chandra P. Belani, T. Dobbs, Slawomir Wojtowicz-Praga, P. Bonomi, Sakkaraiappan Ramalingam, Marianne Cascino
Publikováno v:
Cancer Chemotherapy and Pharmacology. 53:439-444
To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer. In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae213a48edd910943e810c03e6e62801
https://doi.org/10.1007/s00280-003-0752-3
https://doi.org/10.1007/s00280-003-0752-3
Autor:
Slawomir Wojtowicz-Praga
Publikováno v:
Investigational New Drugs. 21:21-32
The immune system is responsible for the early detection and destruction of newly transformed malignant cells. Some transformed cells become immunologically invisible by passive avoidance of immune surveillance (i.e., when tumor cells are immunologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e17ccf87244b053976724aa47f30daf
https://doi.org/10.1023/a:1022951824806
https://doi.org/10.1023/a:1022951824806
Autor:
Pankaj Bhargava, Elizabeth Ness, Naiyer Rizvi, Michael D. Johnson, Michael Oberst, Michael J. Hawkins, Brian M. Norris, Dorraya El-Ashry, Slawomir Wojtowicz-Praga, Yair Fuxman, Said Baidas, John L. Marshall, Neelesh Bangalore
Publikováno v:
Cancer Biology & Therapy. 1:409-416
Purpose: Bryostatin-1 is a compound known to inhibit protein kinase C expression. Clinical trials have focused on administration schedules ranging from 1 hour to 72 hour infusions. Preclinical data suggest that the down regulation of the target PKC o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b98fa798599bca3af3fd535bd0430745
https://doi.org/10.4161/cbt.1.4.17
https://doi.org/10.4161/cbt.1.4.17
Autor:
J. A. Torri, Robert B. Dickson, E Ness, John Marshall, T A Chiodo, Michael D. Johnson, H S Rasmussen, V Steen, Michael J. Hawkins, Slawomir Wojtowicz-Praga, M Sale
Publikováno v:
Journal of Clinical Oncology. 16:2150-2156
PURPOSE This phase I study was performed to evaluate the safety and pharmacokinetics of escalating doses of Marimastat (British Biotech, Inc, Oxford, United Kingdom) in patients with advanced malignancies and to determine the phase II recommended dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2382c7ca9471c3005605626806d3c0be
https://doi.org/10.1200/jco.1998.16.6.2150
https://doi.org/10.1200/jco.1998.16.6.2150
Autor:
Slawomir Wojtowicz-Praga
Publikováno v:
Journal of Immunotherapy. 20:165-177
Many studies show defective immune responses in patients diagnosed with cancer. Most of the diverse nonspecific approaches used to stimulate the immune system to recognize and destroy abnormal tumor cells have limited clinical utility. Attempts to id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b85a0d889669dab3a819ba8b03e5ff
https://doi.org/10.1097/00002371-199705000-00001
https://doi.org/10.1097/00002371-199705000-00001
Publikováno v:
Investigational New Drugs. 15:61-75
The matrix metalloproteinases (MMPs) are a family of at least fifteen secreted and membrane-bound zinc-endopeptidases. Collectively, these enzymes can degrade all of the components of the extracellular matrix, including fibrallar and non-fibrallar co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ba05a51d5e2a4109f092cd764f38404
https://doi.org/10.1023/a:1005722729132
https://doi.org/10.1023/a:1005722729132
Autor:
Jennifer Low, Elizabeth Ness, Michael J. Hawkins, Jeff Moore, James F. Barter, Alice Cole, John L. Marshall, Robert B. Dickson, Peter McCann, Mark Sale, Slawomir Wojtowicz-Praga
Publikováno v:
Investigational New Drugs. 14:193-202
Degradation of basement membrane and extracellular matrix by matrix metalloproteinases (MMPs) is believed to be required for tumor invasion, tumor-induced angiogenesis and vascular invasion. A synthetic hydroxamate, batimastat (also known as BB-94),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54376c71c950a5604b3360d2cf872632
https://doi.org/10.1007/bf00210790
https://doi.org/10.1007/bf00210790
Autor:
Slawomir Wojtowicz-Praga, Jatin J. Shah, Andres Forero-Torres, Feng Roger Luo, T. E. Wood, Catherine Copigneaux, I. Percent, James Posey, Mansoor N. Saleh, Ronda Carlisle
TRA-8 is a murine agonist monoclonal antibody to death receptor 5 (DR5), which is able to trigger apoptosis in DR5 positive human tumor cells without the aid of crosslinking. It has demonstrated cytotoxicity in vitro and in vivo antitumor efficacy to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07717c465a36b2340a73b7d7b85cf015
https://europepmc.org/articles/PMC2883819/
https://europepmc.org/articles/PMC2883819/
Autor:
Beatrice Files, J. Michael Grindel, Lori Luchtman-Jones, Lee Hilliard, Miguel R. Abboud, Thomas D. Coates, Paul Swerdlow, Frans A. Kuypers, Lennette Benjamin, Samir K. Ballas, Slawomir Wojtowicz-Praga
Publikováno v:
Hemoglobin. 30(2)
In a multicenter study (eight centers), we determined secretory phospholipase A(2) (sPLA(2)) levels in patients with sickle cell disease and acute chest syndrome (ACS). The diagnosis of ACS was made according to established criteria. The sPLA2 levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82688385e90fd3683bad30a3bf1faf90
https://pubmed.ncbi.nlm.nih.gov/16798640
https://pubmed.ncbi.nlm.nih.gov/16798640
Autor:
Lee Hilliard, Thomas D. Coates, Lennette Benjamin, J. Michael Grindel, Samir K. Ballas, Miguel R. Abboud, Lori Luchtman-Jones, Slawomir Wojtowicz-Praga, Beatrice Files, Paul Swerdlow
Publikováno v:
Hemoglobin. 28(2)
Acute chest syndrome (ACS) is the most common cause of death in patients with sickle cell anemia. Its management is primarily palliative. We performed a Phase I evaluation of purified poloxamer 188 (a non-ionic surfactant) in the management of ACS. F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec9088d0de7725a4f46af07a1f0cb0c2
https://pubmed.ncbi.nlm.nih.gov/15182051
https://pubmed.ncbi.nlm.nih.gov/15182051